ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0076

Real World Rheumatology Practice of Biologic Monotherapy for the Treatment of Patients with Rheumatoid Arthritis: A Four-year Cohort Study Using a National Claims Database

Ko-Jen Li1, Kuo-Cherh Huang2, Chia-Cheng Lin3 and Chia-Li Chang2, 1National Taiwan University Hospital, Taipei, Taiwan, 2Taipei Medical University, Taipei, Taiwan, 3Chugai Pharma Taiwan Ltd., Taipei, Taiwan

Meeting: ACR Convergence 2022

Keywords: Administrative Data, Biologicals, Health Care, Health Services Research, rheumatoid arthritis

  • Tweet
  • Email
  • Print
Session Information

Date: Saturday, November 12, 2022

Title: Health Services Research Poster I: Lupus, RA, Spondyloarthritis and More

Session Type: Poster Session A

Session Time: 1:00PM-3:00PM

Background/Purpose: There is a growing concern over the rise of polypharmacy, arguably one of the most pressing prescribing challenges. The option of biologic monotherapy is particularly vital for patients with rheumatoid arthritis (RA) who are also likely to receive treatment for other chronic conditions, such as osteoporosis. Hence, the aim of this nationwide population-based study was to provide real world evidence as regards biologic monotherapy for RA patients in Taiwan.

Methods: We identified a retrospective cohort of 6,991 patients who had at least one primary or secondary diagnosis of RA and received initial biologics treatments in outpatients or emergency services between January 1, 2015 and December 31, 2018 from the National Health Insurance Research Database in Taiwan. After excluding ineligible patients (patients who had active tuberculosis prior to the index date, received rituximab, baricitinib or certolizumab pegol as the index treatment, not received any csDMARD, aged below 18 years, or with missing data), ultimately, 5,805 patients were included in the study. We then analyzed incidence rates of biologic monotherapy treatment of those qualified patients.

Results: The overall incidence rate of biologic monotherapy treatment of RA patients was 0.50 per 10 person-years, and the most prescribed medication was tocilizumab (the incident rate = 1.13), followed by tofacitinib (the incident rate = 0.55). Results of Cox proportional hazards regression analyses further asserted that tocilizumab was the most prescribed biologic monotherapy (adjusted hazard ratio = 3.18, 95% CI = 2.36-4.28, p < 0.0001) (Table 1).

Conclusion: There is a need for a monotherapy approach in the treatment of RA patients, and the arsenal of biologic monotherapy is incessantly growing. This nationwide population-based study has demonstrated that in the real world rheumatology practice of biologic monotherapy for RA patients, tocilizumab is the treatment of choice, whereas tofacitinib is the next viable option.

Supporting image 1

Table 1. Univariate and multivariate Cox proportional hazards regression analyses of biologic monotherapy treatment of RA patients


Disclosures: K. Li, None; K. Huang, None; C. Lin, None; C. Chang, None.

To cite this abstract in AMA style:

Li K, Huang K, Lin C, Chang C. Real World Rheumatology Practice of Biologic Monotherapy for the Treatment of Patients with Rheumatoid Arthritis: A Four-year Cohort Study Using a National Claims Database [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/real-world-rheumatology-practice-of-biologic-monotherapy-for-the-treatment-of-patients-with-rheumatoid-arthritis-a-four-year-cohort-study-using-a-national-claims-database/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/real-world-rheumatology-practice-of-biologic-monotherapy-for-the-treatment-of-patients-with-rheumatoid-arthritis-a-four-year-cohort-study-using-a-national-claims-database/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology